MX2021012923A - Microparticulas de liberacion sostenida que contienen deslorelina, y metodo de preparacion de las mismas. - Google Patents

Microparticulas de liberacion sostenida que contienen deslorelina, y metodo de preparacion de las mismas.

Info

Publication number
MX2021012923A
MX2021012923A MX2021012923A MX2021012923A MX2021012923A MX 2021012923 A MX2021012923 A MX 2021012923A MX 2021012923 A MX2021012923 A MX 2021012923A MX 2021012923 A MX2021012923 A MX 2021012923A MX 2021012923 A MX2021012923 A MX 2021012923A
Authority
MX
Mexico
Prior art keywords
sustained
microparticles containing
preparation
release microparticles
method therefor
Prior art date
Application number
MX2021012923A
Other languages
English (en)
Inventor
Ju Hee Kim
Se Yeon Kim
Original Assignee
Inventage Lab Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Inventage Lab Inc filed Critical Inventage Lab Inc
Publication of MX2021012923A publication Critical patent/MX2021012923A/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682Processes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/10Dispersions; Emulsions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/04Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08Peptides having 5 to 11 amino acids
    • A61K38/09Luteinising hormone-releasing hormone [LHRH], i.e. Gonadotropin-releasing hormone [GnRH]; Related peptides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38Cellulose; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0021Intradermal administration, e.g. through microneedle arrays, needleless injectors
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/10Dispersions; Emulsions
    • A61K9/107Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/113Multiple emulsions, e.g. oil-in-water-in-oil
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605Excipients; Inactive ingredients
    • A61K9/1629Organic macromolecular compounds
    • A61K9/1641Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A61K9/1647Polyesters, e.g. poly(lactide-co-glycolide)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5089Processes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Dermatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dispersion Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

De acuerdo con las micropartículas de liberación sostenida que contienen deslorelina, y un método de preparación de las mismas, de la presente invención, se proporcionan micropartículas de liberación sostenida que contienen deslorelina en una formulación para la administración subcutánea, de modo que se puede aliviar el dolor durante la administración a los animales, y un efecto de castración química puede durar de 2 a 36 meses. Además, la presente invención es efectiva como agente de castración química durante 2 a 8 meses, de modo que tiene un excelente efecto de eliminación del olor a verraco.
MX2021012923A 2019-04-30 2020-01-14 Microparticulas de liberacion sostenida que contienen deslorelina, y metodo de preparacion de las mismas. MX2021012923A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR1020190050437A KR102249104B1 (ko) 2019-04-30 2019-04-30 데슬로렐린을 포함하는 서방성 마이크로 입자 및 이의 제조 방법
PCT/KR2020/000657 WO2020222399A1 (ko) 2019-04-30 2020-01-14 데슬로렐린을 포함하는 서방성 마이크로 입자 및 이의 제조 방법

Publications (1)

Publication Number Publication Date
MX2021012923A true MX2021012923A (es) 2021-11-17

Family

ID=73028838

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2021012923A MX2021012923A (es) 2019-04-30 2020-01-14 Microparticulas de liberacion sostenida que contienen deslorelina, y metodo de preparacion de las mismas.

Country Status (15)

Country Link
US (1) US20220202894A1 (es)
EP (1) EP3949951A4 (es)
JP (1) JP7253287B2 (es)
KR (1) KR102249104B1 (es)
CN (1) CN113747884A (es)
AU (1) AU2020266058B2 (es)
BR (1) BR112021021599A2 (es)
CA (1) CA3137819C (es)
CL (1) CL2021002761A1 (es)
IL (1) IL287361A (es)
MX (1) MX2021012923A (es)
PE (1) PE20220491A1 (es)
SG (1) SG11202111521WA (es)
WO (1) WO2020222399A1 (es)
ZA (1) ZA202108300B (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20230124229A (ko) * 2022-02-18 2023-08-25 (주)인벤티지랩 데슬로렐린을 포함하는 서방성 주사용 조성물
WO2024003291A1 (en) 2022-06-30 2024-01-04 Virbac Deslorelin use in chemical castration of a non-human mammal related to pk/pd interaction
WO2024003288A1 (en) * 2022-06-30 2024-01-04 Virbac Deslorelin for attenuation of animal urine odor

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH1045625A (ja) * 1996-04-30 1998-02-17 Takeda Chem Ind Ltd 医薬組成物
EP1007080B1 (en) * 1996-08-30 2007-04-18 Peptech Limited Formulation for the sustained release of peptide agonists and analogues of GnRH
JP4166590B2 (ja) * 2003-02-04 2008-10-15 独立行政法人科学技術振興機構 ダブルエマルション・マイクロカプセル生成装置
DK1824460T3 (en) * 2004-11-10 2015-01-19 Tolmar Therapeutics Inc Stabilized polymeric delivery system
AU2007207618B2 (en) * 2006-01-18 2011-03-24 Foresee Pharmaceuticals Co., Ltd. Pharmaceutical compositions with enhanced stability
BRPI0902699A2 (pt) 2009-07-28 2011-04-12 Marcelo Vivacqua método quìmico para esterilização sexual e eliminação da libido em mamìferos do sexo masculino
KR101583351B1 (ko) * 2014-11-28 2016-01-07 동국제약 주식회사 초기 방출 억제 및 잔류용매 제거율을 향상시킨 서방출성 미립구 및 이의 제조방법
CN105287390A (zh) * 2015-11-20 2016-02-03 北京博恩特药业有限公司 一种长效醋酸亮丙瑞林微球及其制备方法
WO2017150824A1 (ko) * 2016-03-03 2017-09-08 가천대학교 산학협력단 마이크로 니들 및 이의 제조방법

Also Published As

Publication number Publication date
CA3137819A1 (en) 2020-11-05
US20220202894A1 (en) 2022-06-30
AU2020266058B2 (en) 2023-04-06
JP7253287B2 (ja) 2023-04-06
KR102249104B1 (ko) 2021-05-07
CL2021002761A1 (es) 2022-06-03
ZA202108300B (en) 2023-01-25
IL287361A (en) 2021-12-01
EP3949951A1 (en) 2022-02-09
BR112021021599A2 (pt) 2021-12-21
CN113747884A (zh) 2021-12-03
SG11202111521WA (en) 2021-11-29
WO2020222399A1 (ko) 2020-11-05
JP2022530878A (ja) 2022-07-04
KR20200126599A (ko) 2020-11-09
EP3949951A4 (en) 2023-01-18
CA3137819C (en) 2024-01-09
AU2020266058A1 (en) 2021-11-18
PE20220491A1 (es) 2022-04-07

Similar Documents

Publication Publication Date Title
MX2021012923A (es) Microparticulas de liberacion sostenida que contienen deslorelina, y metodo de preparacion de las mismas.
MX2020010603A (es) Extracto de cáñamo para tratamiento de dolor en animales.
JOP20190146A1 (ar) تركيبات حمض أميني وطرق لمعالجة أمراض الكبد
MX2022000027A (es) Extracto de ca?amo para tratamiento del dolor, cancer y epilepsia en animales.
EP4241850A3 (en) Mdm2 inhibitors and combinations thereof
MX2022010274A (es) Uso de dexmedetomidina sublingual para el tratamiento de la agitacion.
MX2020013557A (es) Un esteroide de c21-pirazolilo disustituido con 19-nor c3,3 y métodos de uso del mismo.
PH12021550537A1 (en) Oral formulations of kappa opioid receptor agonists
NZ792518A (en) Formulations for administration of eflornithine
EP4338804A3 (en) Epinephrine spray formulations
MX2023000187A (es) Dosificacion de vibegron para el tratamiento de vejiga sobreactiva.
MX2022015629A (es) Uso de vibegron para tratar vejiga sobreactiva.
WO2016168553A8 (en) Deuterated obeticholic acid
EP4061802A4 (en) COMPOSITIONS AND METHODS FOR IMPROVED ABSORPTION OF ACTIVE INGREDIENTS FOR ANIMAL HEALTH AND NUTRITION
PH12019500154A1 (en) Formulation having improved ph-dependent drug-release characteristics, containing esomeprazole or pharmaceutically acceptable salt thereof
ZA202104960B (en) Methods of treating pain with a thiazoline anti-hyperalgesic
RU2017105451A (ru) Иммуногенная композиция lhrh и ее применение у свиней
UA112418C2 (uk) Терапевтичний болезаспокійливий засіб
MX2020012805A (es) Compuestos para el tratamiento del dolor, composiciones que comprenden los mismos, y metodos para utilizar los mismos.
MX2022005596A (es) Regimen de dosificacion para agentes anti-dll3.
NZ733658A (en) Compositions and methods for chronic use of a weight-gaining compound
MX2020010243A (es) Composiciones bucales y metodos para animales.
MX2021008687A (es) Una composicion para el tratamiento de la periodontitis y la regeneracion de la papila interdental.
MX2020013684A (es) Formulaciones/composiciones que comprenden ibrutinib.
MX2023002625A (es) Composiciones y metodos para proporcionar beneficios para la salud en un animal.